Lataa...
Brexpiprazole as a New Serotonin–Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels
Atypical antipsychotics, used to treat patients with schizophrenia, focus on dopamine-2 (D(2)) plus serotonin-2A (5-HT(2A)) receptor antagonism and currently carry different degrees of certain adverse effects. Brexpiprazole is a new serotonin–dopamine receptor modulator that acts as a partial agonis...
Tallennettuna:
| Julkaisussa: | Innov Clin Neurosci |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Matrix Medical Communications
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7009323/ https://ncbi.nlm.nih.gov/pubmed/32082947 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|